Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

A high-resolution spatial map of the human hypothalamus makes it possible to identify specific cells, determine their exact ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...